



Phoebe Cheung, C. H., Dulyayangkul, P., Heesom, K. J., & Avison, M. B. (2020). Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin Resistance in *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy*.
<https://doi.org/10.1128/AAC.00790-20>

Peer reviewed version

Link to published version (if available):
[10.1128/AAC.00790-20](https://doi.org/10.1128/AAC.00790-20)

[Link to publication record on the Bristol Research Portal](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via American Society for Microbiology at <https://aac.asm.org/content/early/2020/05/20/AAC.00790-20> . Please refer to any applicable terms of use of the publisher.

University of Bristol – Bristol Research Portal

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/brp-terms/>

1 **Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin**
2 **Resistance in *Klebsiella pneumoniae*.**

3

4

5 **Ching Hei Phoebe Cheung^a, Punyawee Dulyayangkul^a, Kate J. Heesom^b, Matthew B.**
6 **Avison^{a#}**

7

8

9 **^aSchool of Cellular & Molecular Medicine, University of Bristol, Bristol. UK**

10 **^b University of Bristol Proteomics Facility, Bristol, UK**

11

12

13 **#Correspondence to: School of Cellular & Molecular Medicine, University of Bristol,**
14 **Bristol, United Kingdom. bimba@bris.ac.uk**

15

16

17

18 **Running Title: Colistin resistance in *K. pneumoniae*.**

19 **Abstract**

20 **Colistin resistance in *Klebsiella pneumoniae* is predominantly caused by mutations**
21 **that increase expression of the *arn* (also known as *pbg* or *pmrF*) operon. Expression is**
22 **activated by the PhoPQ and PmrAB two-component systems. Constitutive PhoPQ**
23 **activation occurs directly by mutation or following loss of MgrB. PhoPQ may also**
24 **cross-activate PmrAB via the linker protein PmrD. Using proteomics, we show that**
25 **MgrB loss causes a wider proteomic effect than direct PhoPQ activation, suggesting**
26 **additional targets for MgrB. Different *mgrB* mutations cause different amounts of Arn**
27 **protein production, which correlated with colistin MIC. Disruption of *phoP* in an *mgrB***
28 **mutant had a reciprocal effect to direct activation of PhoQ in a wild-type background,**
29 **but the regulated proteins showed almost total overlap. Disruption of *pmrD* or *pmrA***
30 **slightly reduced Arn protein production in an *mgrB* mutant, but production was still**
31 **high enough to confer colistin resistance; disruption of *phoP* conferred wild-type Arn**
32 **production and colistin MIC. Activation of PhoPQ directly, or through *mgrB* mutation**
33 **did not significantly activate PmrAB or PmrC production but direct activation of PmrAB**
34 **by mutation did, and also activated Arn production and conferred colistin resistance.**
35 **There was little overlap between the PmrAB and PhoPQ regulons. We conclude that**
36 **under the conditions used for colistin susceptibility testing, PhoPQ-PmrD-PmrAB**
37 **cross-regulation is not significant and that independent activation of PhoPQ or PmrAB**
38 **is the main reason that Arn protein production increases above the threshold required**
39 **for colistin resistance.**

40 Introduction

41 Colistin is increasingly used to treat infections caused by extensively drug resistant Gram-
42 negative bacteria (1). Colistin resistance in carbapenem-resistant *Klebsiella pneumoniae*,
43 which was first reported in 2010 (2-4) is, therefore, a critically important problem. It can be
44 caused by mobile *mcr* genes but by far the most common causes in *K. pneumoniae* and some
45 other Enterobacteriaceae species are chromosomal mutations (5,6). For example, loss-of-
46 function mutations in *mgrB* regularly emerge following colistin therapy in the clinic, and when
47 selecting resistant mutants in the laboratory (7-10). Loss of MgrB causes activation of *arn*
48 operon expression (7). This operon, also referred to as the *pbg* or *pmrF* operon (5) encodes
49 a series of enzymes forming a pathway that modifies lipid A in lipopolysaccharide by adding
50 4-amino-4-deoxy-L-arabinose. This modification has been seen in colistin resistant *K.*
51 *pneumoniae* mutants in many studies (e.g. 11-13). Its effect is to reduce cell surface negative
52 charge, reducing affinity for positively charged colistin, raising its MIC (5).

53 Activation of *arn* operon transcription in *K. pneumoniae* involves two upstream promoters,
54 each targeted by a two-component system response regulator. PhoP targets promoter 1 in
55 response to low magnesium concentrations and PmrA targets promoter 2 in response to high
56 iron concentrations and low pH (14). The dramatic impact that cations and pH have on *arn*
57 promoter activity explains the wide range of medium-dependent colistin MICs observed in the
58 laboratory (15,16). According to a joint CLSI and EUCAST report, colistin susceptibility testing
59 needs to be tightly standardised, therefore, and the gold standard is broth microdilution using
60 colistin sulphate, cation adjusted Muller Hinton broth and with no additives (17)

61 Additional complexity arises in control of *arn* operon transcription in *K. pneumoniae* because
62 the response regulator PhoP can also activate transcription of *pmrD* and PmrD binds PmrA
63 and enhances its activation (14,18). Hence, when low magnesium and high iron occur at the
64 same time, the PmrA-targeted *arn* operon promoter 2 is more strongly activated than it is in
65 the presence of high magnesium and high iron (14).

66 The cognate sensor kinases activating PhoP and PmrA are PhoQ and PmrB, respectively
67 (14). It is generally accepted that loss-of-function mutations in *mgrB* activate *arn* operon
68 transcription in *K. pneumoniae* because MgrB is a direct negative regulator of PhoQ sensor
69 kinase activity, as in some other Enterobacteriaceae species (5). In fact, this is experimentally
70 confirmed only in *Salmonella* spp. (19) but loss of MgrB does constitutively activate PhoPQ in
71 *K. pneumoniae*, leading to constitutively enhanced transcription from *arn* operon promoter 1
72 (14). Specific mutations in PhoPQ also activate *arn* operon transcription and confer colistin
73 resistance or heteroresistance in *K. pneumoniae*, e.g. PhoQ substitutions Asp434Asn (20) or
74 Ala21Ser (21) or PhoP substitution Asp191Tyr (22).

75 Mutations in PmrAB, constitutively activating *arn* operon transcription from promoter 2 have
76 also been found to cause colistin resistance in *K. pneumoniae*. For example, Leu82Arg (23)
77 or Thr157Pro (24) in PmrB, but activation of PmrAB also increases expression of *pmrC*. This
78 encodes an enzyme that modifies lipopolysaccharide by decorating it with
79 phosphoethanolamine, which contributes to colistin resistance in *Salmonella* spp. because it
80 is another way to reduce negative charge on the cell surface (25).

81 A third two-component regulatory system known to be involved in colistin resistance in *K.*
82 *pneumoniae* is CrrAB. Activatory mutations in the sensor kinase CrrB have been identified in
83 colistin resistant clinical isolates (20,26,27). Based on transcriptomic analysis these mutants
84 have increased *arn* operon and *pmrC* transcription (20) and in this they closely resemble
85 PmrAB activatory mutants and indeed *pmrAB* is essential for the activation of *arn* operon and
86 *pmrC* transcription in CrrAB activatory mutants, suggesting direct linkage between these two-
87 component systems (26). One additional effect of CrrAB activation is upregulation of *crrC*
88 transcription (20) and *crrC* is also essential for activation of *arn* operon and *pmrC* transcription
89 in a CrrAB activatory mutant (26). This suggests that CrrC forms the link between activated
90 CrrAB and activation of PmrAB, leading to colistin resistance, but the mechanism by which
91 this link operates is not yet known.

92 The complexity associated with acquisition of colistin resistance in *K. pneumoniae*, means that
93 clinical cases involve a wide range of mutations. In a recent large clinical survey, *mgrB* loss-
94 of-function was the most common mechanism, but in many cases, additional mutations in two-
95 component system genes was seen, and in cases where multiple mutations were seen, a
96 sequential increase in colistin MIC was observed (28)

97 The aim of the work reported here was to use LC-MS/MS shotgun proteomics and targeted
98 mutagenesis to investigate the importance of the MgrB-PhoPQ-PmrD-PmrAB signal
99 transduction pathway to modulate Arn protein and PmrC production, and assess the protein
100 abundance thresholds required for colistin resistance in *K. pneumoniae* stimulated by
101 mutations affecting PhoPQ and/or PmrAB activity.

102

103 **Results and Discussion**

104 *The direct role of PhoPQ and the indirect role of signal transduction from PhoPQ through*
105 *PmrD to PmrAB in Arn protein production and colistin resistance caused by mgrB mutation.*

106 A collection of six *K. pneumoniae* spontaneous single-step mutants were selected in the
107 laboratory using Muller-Hinton agar containing 32 µg.mL⁻¹ of colistin, and in each case, PCR
108 and whole genome sequencing confirmed only mutation in *mgrB* or upstream. Three different
109 mutations were seen, causing the following changes: Gln29STOP in MgrB (found in four
110 colistin resistant mutants here, represented by mutant P21); an A to G transition at -31 relative
111 to the *mgrB* start codon, weakening a putative second -10 promoter sequence (**Figure S1**)
112 (represented by mutant P22); a deletion comprising the region between -19 relative to the start
113 codon, to remove the first 41 amino acids of MgrB (represented by mutant P23).

114 Colistin MICs against these three representative mutants were determined and, in all cases,
115 colistin resistance was confirmed (**Table 1**). Envelope proteomics identified 45 proteins
116 significantly differentially regulated in all three *mgrB* mutants relative to the parent strain, Ecl8
117 (33 up- and 12 down-regulated; **Table S1**). These included the ArnABCDT operon proteins

118 known to be responsible for modification of lipopolysaccharide by the addition of 4-amino-4-
119 deoxy-L-arabinose (5). **Figure 1** shows that Arn protein production is highest in the mutant
120 P23, where MgrB is entirely lost. The *mgrB* nonsense mutant truncated at 29 amino acids,
121 P22 and the *mgrB* promoter mutant P21 both have significantly lower Arn protein production
122 than in P23, implying some residual repressive activity of MgrB in both cases. Overall, P22
123 had the lowest Arn protein production of the three (**Figure 1**). Nonetheless all three mutants
124 are colistin resistant though, as expected based on Arn protein production levels, the highest
125 MIC is against P23 and the lowest against P22 (**Table 1**). This leads to the conclusion that
126 once Arn protein production increases above a certain threshold, colistin resistance is
127 conferred, but that as protein production increases further (P23>P21>P22) MIC also
128 increases.

129 It has been proposed that, in *K. pneumoniae*, *arn* operon gene expression is increased upon
130 *mgrB* mutation through activation of the two-component system PhoPQ, and that in addition,
131 there is a secondary increase through activation of the PmrAB two-component system, with
132 PmrD being necessary for transducing PhoPQ activation into PmrAB activation (5). Using
133 *mgrB* mutant P23 as a starting point, we disrupted *phoP*, *pmrD* and *pmrA*, to test the effects
134 of these mutations on Arn protein production and colistin MIC.

135 Observed Arn protein abundance changes in these regulatory mutants demonstrated the
136 primacy of PhoPQ activation in colistin resistance driven by *mgrB* loss. Arn protein abundance
137 returned to wild-type (**Figure 2**) and colistin MIC fell below the resistance breakpoint (**Table**
138 **1**) upon disruption of *phoP* in the *mgrB* mutant P23. In contrast, our proteomics analysis
139 (**Figure 2**) showed that PmrD and PmrAB play only a minor role in increased Arn protein
140 production seen in an *mgrB* mutant. Only ArnC significantly reduced in abundance following
141 disruption of *pmrA*. There was a larger effect following disruption of *pmrD* (4/5 Arn proteins
142 significantly reduced in abundance) but in neither mutant did any of the Arn proteins fall in
143 abundance significantly below levels seen in the *mgrB* mutants P21 and P22 (**Figure 1**) and
144 not surprisingly therefore, the *pmrA* and *pmrD* mutant derivatives of *mgrB* mutant P23

145 remained colistin resistant (**Table 1**). These data add support for our conclusion that there is
146 a threshold of Arn protein abundance required for colistin resistance. It seems clear that
147 PhoPQ activation alone can support an abundance above this threshold even without any
148 additional effects caused by PmrAB activation.

149

150 *PhoPQ regulated proteins identified following mgrB mutation and PhoQ activation.*

151 Of 45 proteins (i.e. including the Arn proteins) differentially regulated in all three *mgrB* mutants
152 (**Table S1**) 18 of those upregulated in the *mgrB* mutant P23 returned to wild-type levels upon
153 disruption of *phoP* (**Table 2**). These included the five Arn proteins, the response regulator
154 PhoP itself, LpxO, two Mg²⁺ transporters including MgtA, SlyB and MacA. Transcripts
155 representing all these proteins have been seen to be upregulated in *mgrB* loss-of-function and
156 in PhoQ activatory (PhoQ*) colistin resistant clinical isolates relative to colistin susceptible
157 control isolates through transcriptomics (20). Our proteomics analysis reinforces the definition
158 of a core PhoPQ regulon, but a secondary observation is that the majority (27/45) of the protein
159 abundance changes seen in the *mgrB* mutant P23 (**Table S1**) do not occur via activation of
160 PhoPQ; they were not reversed following disruption of *phoP* (**Table 2**). The implication of this
161 finding, made here by comparing otherwise isogenic pairs of strains, is that MgrB interacts
162 with regulatory networks other than PhoPQ in *K. pneumoniae*, though these additional effects
163 are not important for colistin resistance, which was completely reversed following disruption
164 of *phoP* (**Table 1**).

165 In order to further investigate the role of direct PhoPQ activation in colistin resistance, we
166 turned to a colistin resistant, PhoQ* (activatory) mutant that we selected from *K. pneumoniae*
167 clinical isolate KP47 (**Table 1**). Whole genome sequencing identified the mutation causes a
168 Tyr89Asn change in PhoQ. Proteomics comparing KP47 with the PhoQ* mutant derivative
169 revealed that levels of Arn protein production in the PhoQ* mutant were not significantly
170 different from those in the *mgrB* loss-of-function mutant P23 (**Figure 3**). Indeed, despite

171 starting with a different parent strain, significant upregulation of 15/18 proteins seen to become
172 downregulated when *phoP* was disrupted in the Ecl8-derived *mgrB* mutant P23 were also
173 upregulated in the PhoQ* mutant relative to its parent, KP47. This further focussed down onto
174 the core *K. pneumoniae* PhoPQ regulon, which is shown in **Table 2**.

175

176 *Proteins upregulated following activation of PmrAB.*

177 It has been reported that PmrAB activation directly by mutation can confer colistin resistance
178 (23,24) and we were able to select a colistin resistant mutant of clinical isolate KP47 with an
179 activatory mutation in PmrB (**Table 1**). The mutation identified using whole genome
180 sequencing was Thr157Pro. Arn protein abundance in this PmrB* mutant was significantly
181 elevated relative to KP47 in all cases except for ArnB. For all except ArnA and ArnB the extent
182 of abundance increase was like that seen in the PhoQ* derivative of KP47, and the *mgrB*
183 mutant P23 (**Figure 3**). In total, however, only 7/45 proteins significantly up- or down-regulated
184 in the *mgrB* mutant P23 were significantly up- or down-regulated in the PmrB* mutant. As well
185 as the Arn proteins (except ArnB), these were SlyB, LpxO and one Mg²⁺ transporter, which
186 are all part of the core PhoPQ regulon (**Table S1**). Transcripts representing all seven of these
187 PmrAB/PhoPQ dual regulated proteins, plus ArnB have also been seen to be upregulated in
188 clinical isolates with activatory mutations in CrrB (20) which indirectly activates PmrAB (26,27).

189 The fact that ArnB abundance did not increase significantly above the level seen in wild-type
190 KP47 was surprising since the PmrB* mutant is colistin resistant (**Table 1**). This suggested
191 that either significant upregulation of ArnB is not essential for colistin resistance or there is
192 another mechanism involved in colistin resistance in the PmrB* mutant. To identify a possible
193 additional mechanism, we searched the 65 proteins differentially regulated in the PmrB*
194 mutant relative to KP47. Three of those most strongly over-produced were PmrA, PmrB and
195 PmrC (**Figure 4**). Transcription of *pmrC* (also known as *eptA*) is known to be positively
196 controlled by PmrAB in *K. pneumoniae* (24). In *Salmonella* spp. it encodes a

197 phosphoethanolamine transferase, responsible for modifying lipopolysaccharide by
198 decorating it with phosphoethanolamine, and this increases the MIC of colistin (25).

199

200 *Little evidence for PhoPQ-PmrD-PmrAB mediated signal transduction for in vitro colistin*
201 *resistance in K. pneumoniae.*

202 As shown above, disruption of *pmrD* or *pmrA* in an *mgrB* loss-of-function mutant did not reduce
203 Arn protein production below a threshold required for colistin resistance (**Figure 2, Table 1**).
204 It was also interesting to find that PmrA, B or C were not produced above our limit of detection
205 (around 100 times less than the level seen in the PmrB* mutant) in any *mgrB* loss-of-function
206 mutant or in the PhoQ* mutant (**Figure 4**). These two findings lead us to conclude that cross
207 activation of PmrAB (the direct regulator of *pmrC*) following activation of PhoPQ is very limited
208 under the growth conditions used for our analysis.

209 Our observation that the phosphoethanolamine transferase PmrC is unique to the PmrAB-
210 mediated branch of the colistin resistance-mediating regulatory system may well explain why,
211 of multiple studies monitoring the impact of *mgrB* loss-of-function on lipopolysaccharide
212 modification in *K. pneumoniae* (11-13, 29) only one has reported elevated levels of
213 phosphoethanolamine modification (29). Indeed, even in this case, contrary to expectations,
214 the observed modification, and the observed upregulation of *pmrC* expression were both
215 apparently dependent on PhoPQ but not PmrAB, suggesting it was not caused by PhoPQ-
216 PmrD-PmrAB cross-regulation at all (29). Furthermore, the authors showed that *pmrC*
217 disruption in an *mgrB* loss-of-function mutant background only had a small impact on survival
218 in the presence of colistin (29). This implies that even when rarely seen, phosphoethanolamine
219 modification by PmrC has only a minor role in colistin resistance in *K. pneumoniae*. Indeed,
220 an absence of phosphoethanolamine modification has been advocated as a way to identify
221 mutational colistin resistance (as opposed to *mcr*-mediated resistance, which does cause this

222 modification) whether due to *mgrB* loss-of-function mutation, PhoPQ activation or PmrAB
223 activation in *K. pneumoniae* (30).

224 The reason why other earlier seminal reports have placed far higher importance on the cross-
225 activation of PmrAB by PhoPQ via PmrD in *K. pneumoniae* (14,18) could be that they used
226 growth media that caused greater basal activation of PmrAB. It is important to remember that
227 the PmrD linker protein has only experimentally been shown to increase the activation of
228 PmrAB once PmrAB has been activated by an external signal, not to activate PmrAB from the
229 basal state (14,18). Since PmrAB activation is affected by iron concentration and pH, it may
230 be that the medium used for colistin susceptibility testing – and used by us here – does not
231 activate PmrAB in the first place, so there is nothing that PmrD can do to enhance activation,
232 effectively silencing the cross-regulatory pathway. Indeed, it is worth noting that in some
233 Enterobacteriaceae species, e.g. *Enterobacter cloacae*, there is no *pmrD* gene and that
234 PhoPQ and PmrAB work independently to regulate *arn* operon transcription (31).

235 Another explanation for differences between the conclusions of ours and previous work is that
236 previous work relied on measurements of transcript levels. In some cases, small changes in
237 protein abundance are associated with phenotypically relevant changes in antimicrobial
238 susceptibility, as we have shown previously in *K. pneumoniae*, for example upon loss-of-
239 function mutations in *ramR*, which, despite having <5 fold effects on OmpK35 porin and
240 AcrAB-TolC efflux pump production, has large effects on susceptibility to a range of
241 antimicrobial agents from different classes (32). But in some cases, large changes in gene
242 expression are required to have a phenotypic effect when a gene is not highly expressed in
243 the wild-type, for example in the case of OqxAB efflux pump production as controlled by OqxR
244 in *K. pneumoniae*, which needs to increase >10,000 fold to have a phenotypic effect on
245 resistance (33). One major advantage of proteomics is that comparisons of protein abundance
246 can be drawn between different gene products, which is not always the case when transcript
247 levels are measured, since the kinetics of DNA hybridisation can have major influences on
248 signal. This advantage is exemplified here in the context of PmrE production, which we find to

249 be constitutive in *K. pneumoniae*, and not part of the PhoPQ or PmrAB regulons (**Figure 4**),
250 where it is controlled by both regulators in *Salmonella* spp. (5). In the context of PmrB
251 activation in *K. pneumoniae*, constitutive expression of *pmrE* has also been shown by qRT-
252 PCR (26) and in the context of CrrB activation – leading to PmrAB activation – this has been
253 shown through transcriptomics (20). The added value of proteomics is that we can conclude
254 that PmrE, which is an enzyme responsible for driving the committed step for the biosynthesis
255 of 4-amino-4-deoxy-L-arabinose required for colistin resistance (5), is present at levels in wild-
256 type cells similar to the levels of Arn protein produced in colistin resistant mutants rather than
257 its production being constitutive but at low levels (**Figures 3, 4**).

258

259 *Conclusions*

260 We conclude that colistin resistance caused by PhoPQ activation in conditions defined for
261 colistin susceptibility testing – i.e. in most clinical cases (28) – is due almost exclusively to
262 direct Arn protein upregulation. Whilst PmrAB activation can also cause Arn protein
263 upregulation and colistin resistance, there is no evidence for significant activation of PmrAB
264 via PmrD as an additional mechanism for upregulating Arn proteins following PhoPQ activation
265 under these growth conditions. We also conclude that the level of Arn protein upregulation
266 dictates colistin MIC. It is interesting to note, therefore that clinical isolates with multiple
267 mutations activating PhoPQ can be found, where there is an additive effect on colistin MIC
268 (28). The implication is that real-world colistin usage in the clinic in some cases selects for
269 mutations or combinations of mutations that confer colistin MICs above the currently defined
270 resistance breakpoint.

271

272

273

274 **Experimental**

275 *Materials, bacterial isolates, selection and generation of mutants*

276 Chemicals were from Sigma and growth media from Oxoid, unless otherwise stated. Strains
277 used were *K. pneumoniae* Ecl8 (34), plus the clinical isolate KP47 (35). To select colistin
278 resistant mutants, one hundred microlitre aliquots of overnight cultures of the parent strain
279 grown in Cation Adjusted Muller-Hinton Broth (CAMHB) were spread onto Mueller-Hinton Agar
280 containing 32 µg.mL⁻¹ colistin, which were then incubated for 24 h. Insertional inactivation of
281 *phoP*, *pmrD*, or *pmrA* was performed using the pKNOCK suicide plasmid (36). The *phoP*,
282 *pmrD* and *pmrA* DNA fragments were amplified with Phusion High-Fidelity DNA Polymerase
283 (NEB, UK) from *K. pneumoniae* Ecl8 genomic DNA by using primers listed in **Table S2**. Each
284 PCR product was ligated into the pKNOCK-GM at the *Sma*I site. The recombinant plasmid
285 was then transferred into *K. pneumoniae* cells by conjugation. Mutants were selected for
286 gentamicin non-susceptibility (5 µg.mL⁻¹) and the mutation was confirmed by PCR using
287 primers listed in **Table S2**.

288

289 *Determining MICs of colistin*

290 MICs were determined using CLSI broth microtitre assays (37) and interpreted using published
291 breakpoints (38). Briefly, a PBS bacterial suspension was prepared to obtain a stock of
292 OD₆₀₀=0.01. The final volume in each well of a 96-well cell culture plate (Corning Costar) was
293 200 µL and included 20 µL of the bacterial suspension. Bacterial growth was determined after
294 20 h of incubation by measuring OD₆₀₀ values using a POLARstar Omega spectrophotometer
295 (BMG Labtech).

296

297

298

299 *Proteomics*

300 500 μ L of an overnight CAMHB culture were transferred to 50 mL CAMHB and cells were
301 grown at 37°C to 0.6 OD₆₀₀. Cells were pelleted by centrifugation (10 min, 4,000 \times g, 4°C) and
302 resuspended in 30 mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 s
303 on, 0.5 s off for 3 min at amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and
304 Materials Inc., Newton, Connecticut, USA). The sonicated samples were centrifuged at 8,000
305 rpm (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 4°C to pellet intact cells and large
306 cell debris. For envelope preparations, the supernatant was subjected to centrifugation at
307 20,000 rpm for 60 min at 4°C using the above rotor to pellet total envelopes. To isolate total
308 envelope proteins, this total envelope pellet was solubilised using 200 μ L of 30 mM Tris-HCl
309 pH 8 containing 0.5% (w/v) SDS.

310 LC-MS/MS shotgun proteomic analysis was performed as described previously (32). Analysis
311 was repeated three times for each parent and mutant strain, each using a separate batch of
312 cells. Specific protein abundance was normalised based on the average abundance of the 50
313 most abundant proteins in each sample. Comparisons of normalised abundance between
314 samples used an unpaired t-test, and significance was defined with $p < 0.05$. Fold-change in
315 abundance between strains was calculated by first calculating average normalised abundance
316 across the three samples representing each strain.

317

318 *Whole genome sequencing to identify mutations*

319 Whole genome resequencing was performed by MicrobesNG (Birmingham, UK) on a HiSeq
320 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic
321 (39) and assembled into contigs using SPAdes 3.10.1 (<http://cab.spbu.ru/software/spades/>).
322 Assembled contigs were mapped to the *K. pneumoniae* Ecl8 reference genome (GenBank
323 accession number GCF_000315385.1) (34), obtained from GenBank by using progressive
324 Mauve alignment software (40).

325

326 **Acknowledgments**

327 This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance
328 Cross Council Initiative supported by the seven United Kingdom research councils and the
329 National Institute for Health Research. Genome sequencing was provided by MicrobesNG
330 (<http://www.microbesng.uk/>), which is supported by the BBSRC (grant number
331 BB/L024209/1).

332

333 **We declare no conflicts of interest.**

334 **Figure Legends**

335

336 **Figure 1. Arn protein abundance in parent strain Ecl8 versus three *mgrB* mutants.**

337 Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein
338 in a sample are presented normalised using the average abundance of the 50 most abundant
339 proteins in that sample. Data for three biological replicates of parent (Ecl8) and *mgrB* mutants
340 (P21, P22 and P23) are presented as mean +/- Standard Error of the Mean. All mutants have
341 statistically significantly increased production of all Arn proteins relative to Ecl8 based on a t-
342 test ($p < 0.05$).

343

344 **Figure 2. Arn protein abundance in *mgrB* loss-of-function mutant P23 versus its *phoP*,
345 *pmrD* and *pmrA* loss-of-function mutant derivatives.**

346 Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein
347 in a sample are presented normalised using the average abundance of the 50 most abundant
348 proteins in that sample. Data for three biological replicates of parent (P23) and mutants where
349 *phoP*, *pmrD* or *pmrA* had been insertionally inactivated (PhoP-, PmrD- or PmrA-) are
350 presented as mean +/- Standard Error of the Mean. All PhoP- mutants have statistically
351 significantly reductions in production of all Arn proteins relative to P23 based on a t-test
352 ($p < 0.05$). For PmrD- and PmrA- mutants, significant changes relative to P23 are noted with a
353 star.

354

355 **Figure 3. Arn protein abundance in *mgrB* mutant P23 versus clinical isolate KP47 and
356 PhoQ* or PmrB* (activatory) mutant derivatives.**

357 Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein
358 in a sample are presented normalised using the average abundance of the 50 most abundant

359 proteins in that sample. Data for three biological replicates of parent (KP47) and mutants
360 where PhoQ or PmrA have been activated, compared with the *mgrB* loss-of-function mutant
361 P23 are presented as mean +/- Standard Error of the Mean. All Arn proteins, and all Arn
362 proteins except ArnB are significantly upregulated relative to KP47 in its PhoQ* mutant, and
363 PmrB* mutant, respectively based on a t-test ($p < 0.05$). For the PmrB* mutant, significantly
364 lower abundances relative to the PhoQ* mutant are noted with a star.

365

366 **Figure 4. PmrA, B, C and E protein abundance in *mgrB* mutant P23 versus clinical**
367 **isolate KP47 and PhoQ* or PmrB* (activatory) mutant derivatives.**

368 Strains were grown in CAMHB and raw envelope protein abundance data for each Pmr protein
369 in a sample are presented normalised using the average abundance of the 50 most abundant
370 proteins in that sample. Data for three biological replicates of parent (KP47) and mutants
371 where PhoQ or PmrA have been activated, compared with the *mgrB* loss-of-function mutant
372 P23 are presented as mean +/- Standard Error of the Mean. PmrA, B and C were significantly
373 upregulated relative to KP47 in its PmrB* mutant based on a t-test ($p < 0.05$). No other
374 differences were statistically significant.

375 **Tables**

376

377 **Table 1: MICs of colistin against clinical isolates and mutant derivatives.**

378	Strain/ mutant	Colistin MIC ($\mu\text{g.mL}^{-1}$)
379	Ecl8	1
380	P21 (<i>mgrB</i>)	64
381	P22 (<i>mgrB</i>)	32
382	P23 (<i>mgrB</i>)	128
383	P23 <i>phoP</i>	2
384	P23 <i>pmrD</i>	64
385	P23 <i>pmrA</i>	64
386	KP47	2
387	KP47 PhoQ*	64
388	KP47 PmrB*	32
389		

390

391 Values reported are the modes of three repetitions. Shading indicates resistance according to
392 susceptibility breakpoints set by the CLSI (38).

393

394 **Table 2: Significant changes in envelope protein abundance seen in *K. pneumoniae* mutant P23 *phoP* versus P23**

395 Strains were grown in CAMHB and raw abundance data for each protein in a sample are presented normalised using the average abundance of
 396 the 50 most abundant proteins in that sample. Data for three biological replicates of colistin resistant *mgrB* mutant P23 and its *phoP* insertionally
 397 inactivated derivative. Proteins listed are those significantly (based on t-test) differently up- (fold change >1) or down-regulated (fold change <1)
 398 in P23 *phoP* versus P23; considering only proteins that were oppositely regulated in P23 compared with its colistin susceptible parent, Ecl8, as
 399 listed in **Table S1**. Shading indicates proteins not upregulated in the PhoQ* (activatory) mutant of *K. pneumoniae* clinical isolate KP47 relative to
 400 KP47; the other 15/18 proteins not shaded are therefore considered the core PhoPQ regulon, see text. Stars indicate proteins encoded by
 401 transcripts upregulated in a *K. pneumoniae* PhoQ activatory mutant (20).


Accession	Description	P23 1	P23 2	P23 3	<i>phoP</i> 1	<i>phoP</i> 2	<i>phoP</i> 3	Fold Change	t-test
A6T4W9	GlnD	0.005	0.011	0.009	0.005	0.002	0.003	0.408	0.027
A6T5U9	Putative periplasmic binding protein	0.036	0.029	0.024	0.000	0.000	0.000	<0.01	0.001
A6T5Y8	Mg ²⁺ transport ATPase*	0.033	0.041	0.032	0.002	0.000	0.000	0.018	<0.005
A6T6X6	MacA*	0.016	0.024	0.021	0.006	0.010	0.002	0.305	0.005
A6T7D1	Hypothetical Protein	0.017	0.021	0.022	0.016	0.014	0.013	0.714	0.019
A6T7F8	Thymidylate kinase	0.021	0.018	0.016	0.016	0.013	0.011	0.740	0.039
A6T7J8	PhoP*	0.087	0.105	0.125	0.011	0.000	0.000	0.036	<0.005
A6T9Y9	SlyB*	1.833	2.191	1.513	0.669	0.634	0.697	0.361	0.002
A6TBQ4	Lipid A 1-diphosphate synthase	0.122	0.153	0.122	0.012	0.000	0.000	0.030	<0.005
A6TBT1	ApbE*	0.043	0.045	0.038	0.014	0.005	0.005	0.189	<0.005
A6TCT2	LpxO*	0.048	0.052	0.037	0.009	0.000	0.003	0.081	0.001
A6TF96	ArnT*	0.040	0.070	0.035	0.000	0.000	0.000	<0.01	0.006
A6TF97	ArnD*	0.071	0.041	0.041	0.000	0.000	0.000	<0.01	0.004
A6TF98	ArnA*	0.496	0.309	0.321	0.000	0.000	0.000	<0.01	<0.005
A6TF99	ArnC*	0.236	0.313	0.247	0.000	0.000	0.000	<0.01	<0.005
A6TFA0	ArnB*	0.098	0.051	0.053	0.000	0.000	0.000	<0.01	0.006
A6THH1	MgtA*	0.025	0.036	0.031	0.000	0.000	0.000	<0.01	<0.005
A6THT5	Putative porin	0.639	0.794	0.614	0.053	0.054	0.058	0.081	<0.005

402

403 **Figures**

404 **Figure 1**


405



406


407 **Figure 2**

408




409

410 **Figure 3**



419 **Figure 4**

420



421

422 **References**

- 423 1. Durante-Mangoni E, Andini R, Zampino R. 2019. Management of carbapenem-resistant
424 Enterobacteriaceae infections. Clin Microbiol Infect 25:943-950.
- 425 2. Tóth A, Damjanova I, Puskás E, Jánvári L, Farkas M, Dobák A, Böröcz K, Pászti J. 2010.
426 Emergence of a colistin-resistant KPC-2-producing *Klebsiella pneumoniae* ST258 clone in
427 Hungary. Eur J Clin Microbiol Infect Dis 29:765-769.
- 428 3. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D.
429 2010. Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 beta-
430 lactamase resistant to colistin. J Hosp Infect 76:70-73.
- 431 4. Elemam A, Rahimian J, Doymaz M. 2010. In vitro evaluation of antibiotic synergy for
432 polymyxin B-resistant carbapenemase-producing *Klebsiella pneumoniae*. J Clin Microbiol
433 48:3558-3562.
- 434 5. Jeannot K, Bolard A, Plésiat P. 2017. Resistance to polymyxins in Gram-negative
435 organisms. Int J Antimicrob Agents 49:526-535.
- 436 6. Deshpande LM, Hubler C, Davis AP, Castanheira M. 2019. Updated Prevalence of *mcr*-
437 Like Genes among *Escherichia coli* and *Klebsiella pneumoniae* in the SENTRY Program
438 and Characterization of *mcr*-1.11 Variant. Antimicrob Agents Chemother 63:e02450-18.
- 439 7. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, Gaibani P, Rossolini
440 GM. 2013. In vivo emergence of colistin resistance in *Klebsiella pneumoniae* producing
441 KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP *mgrB*
442 regulator. Antimicrob Agents Chemother 57:5521-5526.
- 443 8. López-Camacho E, Gómez-Gil R, Tobes R, Manrique M, Lorenzo M, Galván B, Salvarelli
444 E, Moatassim Y, Salanueva IJ, Pareja E, Codoñer FM, Alvarez-Tejado M, Garcillán-Barcia
445 MP, De la Cruz F, Mingorance J. 2014. Genomic analysis of the emergence and evolution
446 of multidrug resistance during a *Klebsiella pneumoniae* outbreak including carbapenem
447 and colistin resistance. J Antimicrob Chemother 69:632-636.
- 448 9. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K,

- 449 Vatopoulos A, Rossolini GM; COLGRIT Study Group. 2014. MgrB inactivation is a
450 common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of
451 clinical origin. *Antimicrob Agents Chemother* 58:5696-5703.
- 452 10. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Türkoglu S, Nordmann P. 2015.
453 The *mgrB* gene as a key target for acquired resistance to colistin in *Klebsiella pneumoniae*.
454 *J Antimicrob Chemother* 70:75-80.
- 455 11. Helander IM, Kato Y, Kilpeläinen I, Kostianen R, Lindner B, Nummila K, Sugiyama T,
456 Yokochi T. 1996. Characterization of lipopolysaccharides of polymyxin-resistant and
457 polymyxin-sensitive *Klebsiella pneumoniae* O3. *Eur J Biochem* 237:272-278.
- 458 12. Leung LM, Cooper VS, Rasko DA, Guo Q, Pacey MP, McElheny CL, Mettus RT, Yoon
459 SH, Goodlett DR, Ernst RK, Doi Y. 2017. Structural modification of LPS in colistin-
460 resistant, KPC-producing *Klebsiella pneumoniae*. *J Antimicrob Chemother* 72:3035-3042.
- 461 13. Jasim R, Baker MA, Zhu Y, Han M, Schneider-Futschik EK, Hussein M, Hoyer D, Li J,
462 Velkov T. 2018. A Comparative Study of Outer Membrane Proteome between Paired
463 Colistin-Susceptible and Extremely Colistin-Resistant *Klebsiella pneumoniae* Strains. *ACS*
464 *Infect Dis* 4:1692-1704.
- 465 14. Mitrophanov AY, Jewett MW, Hadley TJ, Groisman EA. 2008. Evolution and dynamics of
466 regulatory architectures controlling polymyxin B resistance in enteric bacteria. *PLoS Genet*
467 4:e1000233.
- 468 15. Humphries RM, Green DA, Schuetz AN, Bergman Y, Lewis S, Yee R, Stump S, Lopez M,
469 Macesic N, Uhlemann AC, Kohner P, Cole N, Simner PJ. 2019. Multicenter Evaluation of
470 Colistin Broth Disk Elution and Colistin Agar Test: a Report from the Clinical and
471 Laboratory Standards Institute. *J Clin Microbiol* 2019 57:e01269-19.
- 472 16. Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, Walsh
473 TR, Tyrrell JM. 2018. Clinical Validation of SensiTest Colistin, a Broth Microdilution-Based
474 Method To Evaluate Colistin MICs. *J Clin Microbiol* 56:e01523-17.
- 475 17. CLSI-EUCAST Polymyxin Breakpoints Working Group. 2016. Recommendations for MIC
476 determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST

477 Polymyxin Breakpoints Working Group. EUCAST
478 [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Rec](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf)
479 [ommendations_for_MIC_determination_of_colistin_March_2016.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf).

480 18. Cheng HY, Chen YF, Peng HL. 2010. Molecular characterization of the PhoPQ-PmrD-
481 PmrAB mediated pathway regulating polymyxin B resistance in *Klebsiella pneumoniae*
482 CG43. J Biomed Sci 17:60.

483 19. Lippa AM, Goulian M. 2009. Feedback inhibition in the PhoQ/PhoP signaling system by
484 a membrane peptide. PLoS Genet 5:e1000788.

485 20. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR,
486 Bonomo RA, Adams MD. 2015. Genomic and transcriptomic analyses of colistin-resistant
487 clinical isolates of *Klebsiella pneumoniae* reveal multiple pathways of resistance.
488 Antimicrob Agents Chemother 59:536-543.

489 21. Halaby T, Kucukkose E, Janssen AB, Rogers MR, Doorduyn DJ, van der Zanden AG, Al
490 Naiemi N, Vandenbroucke-Grauls CM, van Schaik W. 2016. Genomic Characterization of
491 Colistin Heteroresistance in *Klebsiella pneumoniae* during a Nosocomial Outbreak.
492 Antimicrob Agents Chemother 60:6837-6843.

493 22. Jayol A, Nordmann P, Brink A, Poirel L. 2015. Heteroresistance to colistin in *Klebsiella*
494 *pneumoniae* associated with alterations in the PhoPQ regulatory system. Antimicrob
495 Agents Chemother 59:2780-2784.

496 23. Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P, D'Andrea MM, Rossolini
497 GM. 2014. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-
498 producing *Klebsiella pneumoniae* is associated with low-dosage colistin treatment.
499 Antimicrob Agents Chemother 58:4399-4403.

500 24. Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P. 2014. Resistance to colistin
501 associated with a single amino acid change in protein PmrB among *Klebsiella pneumoniae*
502 isolates of worldwide origin. Antimicrob Agents Chemother 58:4762-4766.

503 25. Lee H, Hsu FF, Turk J, Groisman EA. 2004. The PmrA-regulated *pmrC* gene mediates
504 phosphoethanolamine modification of lipid A and polymyxin resistance in *Salmonella*

- 505 *enterica*. J Bacteriol 186:4124-4133.
- 506 26. Cheng YH, Lin TL, Lin YT, Wang JT. 2016. Amino Acid Substitutions of CrrB Responsible
507 for Resistance to Colistin through CrrC in *Klebsiella pneumoniae*. Antimicrob Agents
508 Chemother 60:3709-3716.
- 509 27. Jayol A, Nordmann P, Brink A, Villegas MV, Dubois V, Poirel L. 2017. High-Level
510 Resistance to Colistin Mediated by Various Mutations in the *crrB* Gene among
511 Carbapenemase-Producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother
512 61:e01423-17.
- 513 28. Macesic N, Nelson B, Mcconville TH, Giddins MJ, Green DA, Stump S, Gomez-Simmonds
514 A, Annavajhala MK, Uhlemann AC. 2020. Emergence of Polymyxin Resistance in Clinical
515 *Klebsiella pneumoniae* Through Diverse Genetic Adaptations: A Genomic, Retrospective
516 Cohort Study. Clin Infect Dis 70:2084-2091.
- 517 29. Kidd TJ, Mills G, Sá-Pessoa J, Dumigan A, Frank CG, Insua JL, Ingram R, Hopley L,
518 Bengoechea JA. 2017. A *Klebsiella pneumoniae* antibiotic resistance mechanism that
519 subdues host defences and promotes virulence. EMBO Mol Med 9:430-447.
- 520 30. Dortet L, Broda A, Bernabeu S, Glupczynski Y, Bogaerts P, Bonnin R, Naas T, Filloux A,
521 Larrouy-Maumus G. 2020. Optimization of the MALDIxin test for the rapid identification of
522 colistin resistance in *Klebsiella pneumoniae* using MALDI-TOF MS. J Antimicrob
523 Chemother 75:110-116.
- 524 31. Guérin F, Isnard C, Sinel C, Morand P, Dhalluin A, Cattoir V, Giard JC. 2016. Cluster-
525 dependent colistin hetero-resistance in *Enterobacter cloacae* complex. J Antimicrob
526 Chemother 71:3058-3061.
- 527 32. Jiménez-Castellanos JC, Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Schneiders T,
528 Heesom KJ, Avison MB. 2018. Envelope proteome changes driven by RamA
529 overproduction in *Klebsiella pneumoniae* that enhance acquired β -lactam resistance. J
530 Antimicrob Chemother 73:88-94.
- 531 33. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Avison MB. 2018. Impact of
532 OqxR loss of function on the envelope proteome of *Klebsiella pneumoniae* and

533 susceptibility to antimicrobials. J Antimicrob Chemother 73:2990-2996.

534 34. Fookes M, Yu J, De Majumdar S, Thomson N, Schneiders T. 2013. Genome Sequence of
535 *Klebsiella pneumoniae* Ecl8, a Reference Strain for Targeted Genetic Manipulation.
536 Genome Announc 1:e00027-12.

537 35. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-Castellanos JC,
538 Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP, Avison MB. 2018. Prediction
539 of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using
540 Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes.
541 Antimicrob Agents Chemother 62:e01814-17.

542 36. Alexeyev MF. 1999. The pKNOCK series of broad-host-range mobilizable suicide vectors
543 for gene knockout and targeted DNA insertion into the chromosome of Gram-negative
544 bacteria. BioTechniques 26:824-828.

545 37. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution
546 antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th
547 ed. Clinical and Laboratory Standards Institute, Wayne, PA.

548 38. Clinical and Laboratory Standards Institute. 2019. M100-S29. Performance standards for
549 antimicrobial susceptibility testing; twenty-ninth informational supplement. An
550 informational supplement for global application developed through the Clinical and
551 Laboratory Standards Institute consensus process. Clinical and Laboratory Standards
552 Institute, Wayne, PA.

553 39. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina
554 sequence data. Bioinformatics 30:2114–2120.

555 40. Darling AE, Mau B, Perna NT, Batzoglou S, Zhong Y. 2010. progressiveMauve: multiple
556 genome alignment with gene gain, loss and rearrangement. PLoS One 5:e11147.